… pancreatic cancer has a dismal prognosis with a median survival of 3–5 months in untreated
disease. Since the introduction of gemcitabine, pancreatic cancer may … -agent gemcitabine. …

… the regulation of gemcitabine-induced cytotoxicity in pancreatic cancer has not been …
pancreatic tumors and pancreatic cancer cell lines compared with normal pancreas and pancreatic …

… with gemcitabine in our study are in line with the results of these studies, as well as the
findings in other trials of single-agent gemcitabine in patients with advanced pancreatic cancer. …

… among patients with metastatic pancreatic cancer, 12 we anticipated that the 3-… gemcitabine
therapy, which would correspond to a hazard ratio for cancer-related event, second cancer, …

… -agent gemcitabine with gemcitabine plus irinotecan in 342 advanced pancreatic cancer
patients. … evaluation of the prolonged infusion strategy with gemcitabine in pancreatic cancer. …

… activity in combination with gemcitabine in murine models of pancreatic cancer. In particular,
nab-paclitaxel improved the intratumoral concentration of gemcitabine. On the basis of …

… pathways involved in the resistance of pancreatic cancer cells to gemcitabine, in the hope of
… human pancreatic cancer cell lines showing different degrees of resistance to gemcitabine …

… Gemcitabine has modest activity in pancreatic cancer, a limited positive improvement on
a … , gemcitabine warrants further investigation in combination studies in pancreatic cancer. …

… with resected pancreatic cancer. Gemcitabine is known to be the most effective agent in
advanced disease as well as an effective agent in patients with resected pancreatic cancer. …

… Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma
may predict survival in patients who receive adjuvant gemcitabine after resection. …